GIVLAARI

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Estonia, France, Ireland, Israel, Italy, Japan, Lithuania, Poland, Romania, Spain.

Active ingredients

The drug GIVLAARI contains one active pharmaceutical ingredient (API):

1	Givosiran UNII 5XE21E41RT - GIVOSIRAN SODIUM
	Givosiran is a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of aminolevulinic acid synthase 1 (ALAS1) messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference, resulting in a reduction of induced liver ALAS1 mRNA towards normal. This leads to reduced circulating levels of neurotoxic intermediates aminolevulinic acid (ALA) and porphobilinogen (PBG), the key causal factors of attacks and other disease manifestations of AHP.
	Read more about Givosiran

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GIVLAARI Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
GIVLAARI Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AX16		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AX Various alimentary tract and metabolism products
Discover more medicines within A16AX16

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	587920100000207
CA	Health Products and Food Branch	02506343
EE	Ravimiamet	1814138
ES	Centro de información online de medicamentos de la AEMPS	1201428001
FR	Base de données publique des médicaments	68318874
IL	מִשְׂרַד הַבְּרִיאוּת	8769
IT	Agenzia del Farmaco	048516013
JP	医薬品医療機器総合機構	3999461A1023
LT	Valstybinė vaistų kontrolės tarnyba	1089519
PL	Rejestru Produktów Leczniczych	100433397
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66769001
US	FDA, National Drug Code	71336-1001